You are here:Home-Chemical Inhibitors & Agonists-GPCR-Orexin Receptor-Firazorexton
Firazorexton

Chemical Structure : Firazorexton

CAS No.: 2274802-95-6

Firazorexton (TAK-994, TAK994)

Catalog No.: PC-38360Not For Human Use, Lab Use Only.

Firazorexton (TAK-994) is a potent, selective, orally available and brain-penetrant agonist of orexin 2 receptor (OX2R) with EC50 of 19 nM against recombinant human OX2R, 700-fold selectivity against OX1R.

Packing Price Stock Quantity
1 mg $258 In stock
5 mg $458 In stock
10 mg $728 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Firazorexton (TAK-994) is a potent, selective, orally available and brain-penetrant agonist of orexin 2 receptor (OX2R) with EC50 of 19 nM against recombinant human OX2R, 700-fold selectivity against OX1R.
TAK-994 binds to hOX2R in a monophasic manner, with pKD of 7.07 and Bmax of 4.03 pmol/mg protein.
TAK-994 increased calcium mobilization in hOX2R/CHO-K1 cells in a dose-dependent manner with an EC50 value of 19 nM, with no effect on calcium mobilization using hOX1R/CHO-K1 cells.
TAK-994 dose-dependently increased IP1 contents with EC50 value of 16 nM in hOX2R/CHO-EA cell, increased β-arrestin recruitment with EC50 of 4.5 nM.
TAK-994 induced phosphorylation of ERK1/2 with EC50 of 19 nM and phosphorylation of CREB with EC50 of 2.9 nM nM, respectively, in hOX2R/CHO-EA cells.
TAK-994 (30 mg/kg, by mouth) significantly increased total wakefulness time in C57BL/6J mice, did not affect total wakefulness time in OX2R KO mice.

Physicochemical Properties

M.Wt 470.507
Formula C22H25F3N2O4S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3',5'-trifluoro-[1,1'-biphenyl]-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide

References

1. Takashi Ishikawa, et al. J Pharmacol Exp Ther. 2023 Jun;385(3):193-204.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: